Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

被引：41

作者：

Lo Re M. ^{[1
]}

Capobianco M. ^{[2
]}

Ragonese P. ^{[1
]}

Realmuto S. ^{[1
]}

Malucchi S. ^{[2
]}

Berchialla P. ^{[3
]}

Salemi G. ^{[1
]}

Bertolotto A. ^{[2
]}

机构：

[1] Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo

[2] Regional Multiple Sclerosis Centre, San Luigi Gonzaga Hospital, Orbassano

[3] Department of Clinical and Biological Sciences, University of Turin, Torino

来源：

Neurology and Therapy | 2015年 / 4卷 / 2期

关键词：

Disease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies;

D O I：

10.1007/s40120-015-0038-9

中图分类号：

学科分类号：

摘要：

Introduction: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods: Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results: Overall, 72 of 132 patients (54.5%) had relapses after NTZ discontinuation and 60 of 125 patients (48%), who had magnetic resonance imaging, had radiological reactivation. Rebound was observed in 28 of 132 patients (21.2%). A higher number of relapses in the 2 years before NTZ treatment, a longer washout period, and a lower number NTZ infusions correlated with reactivation and rebound. Untreated patients (n = 37) had higher clinical and radiological activity and rebound in comparison to patients receiving DMDs. Moreover, a lower risk of relapses was found in patients treated with second-line therapies (NTZ and fingolimod) than in those treated with first-line therapies (interferon beta, glatiramer acetate, teriflunomide, azathioprine). Interestingly, no disease reactivation in off-label treatment (rituximab, autologous hematopoietic stem cell transplantation) was observed. Conclusion: NTZ discontinuation is a risk for MS reactivation and rebound. An alternative treatment should be promptly resumed mainly in patients with a previous very active disease course and with a shorter NTZ therapy. Second-line therapies demonstrate superiority in preventing relapses after NTZ discontinuation. © 2015, The Author(s).

引用

页码：147 / 157

页数：10

共 37 条

[21]

Laroni A., Brogi D., Milesi V., Et al., Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption, Mult Scler, 19, 9, pp. 1236-1237, (2012)

[22]

Jokubaitis V., Li V., Kalincik T., Et al., Fingolimod after natalizumab and the risk of short-term relapse, Neurology, 82, pp. 1204-1211, (2014)

[23]

Iaffaldano P., Lucisano G., Pozzilli C., Et al., Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis, Brain, 138, pp. 3275-3286, (2015)

[24]

Daelman L., Maitrot A., Maarouf A., Et al., Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal, Mult Scler, 11, 18, pp. 1647-1649, (2012)

[25]

Centonze D., Rossi S., Rinaldi F., Gallo P., Severe relapses under Fingolimod treatment prescribed after natalizumab, Neurology, 79, pp. 2004-2006, (2012)

[26]

Rinaldi F., Seppi D., Calabrese M., Et al., Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings, Mult Scler, 18, (2012)

[27]

Kappos L., Radue E.W., Comi G., TOFINGO study group. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS, Neurology, 85, pp. 29-40, (2015)

[28]

Capobianco M., di Sapio A., Malentacchi M., Et al., No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation, Eur J Neurol, 22, 3, pp. 585-587, (2015)

[29]

Stuve O., Marra C.M., Jerome K.R., Et al., Immune surveillance in multiple sclerosis patients treated with natalizumab, Ann Neurol, 59, pp. 743-747, (2006)

[30]

Pavlina T., Subramanyam M., Bloomgren G., Et al., Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab associated progressive multifocal leukoencephalopathy, Ann Neurol, 76, pp. 802-812, (2014)

← 1 2 3 4 →